199 related articles for article (PubMed ID: 35001204)
21. Perimacular Atrophy Following Voretigene Neparvovec-Rzyl Treatment in the Setting of Previous Contralateral Eye Treatment With a Different Viral Vector.
Ku CA; Igelman AD; Huang SJ; Bailey ST; Lauer AK; Duncan JL; Weleber RG; Yang P; Pennesi ME
Transl Vis Sci Technol; 2024 Jun; 13(6):11. PubMed ID: 38888288
[TBL] [Abstract][Full Text] [Related]
22. Safety and Long-Term Efficacy of AAV4 Gene Therapy in Patients with RPE65 Leber Congenital Amaurosis.
Le Meur G; Lebranchu P; Billaud F; Adjali O; Schmitt S; Bézieau S; Péréon Y; Valabregue R; Ivan C; Darmon C; Moullier P; Rolling F; Weber M
Mol Ther; 2018 Jan; 26(1):256-268. PubMed ID: 29033008
[TBL] [Abstract][Full Text] [Related]
23. [Gene therapy treatment based on an ophthalmic indication in hereditary retinal dystrophy caused by RPE65 biallelic gene mutation.].
Vizvári E; Smeller L; Jánossy Á; Lőrincz M; Janáky M; Tóth-Molnár E
Orv Hetil; 2022 Nov; 163(48):1923-1931. PubMed ID: 36436058
[TBL] [Abstract][Full Text] [Related]
24. Gene Therapy with Voretigene Neparvovec Improves Vision and Partially Restores Electrophysiological Function in Pre-School Children with Leber Congenital Amaurosis.
Gerhardt MJ; Priglinger CS; Rudolph G; Hufendiek K; Framme C; Jägle H; Salchow DJ; Anschütz A; Michalakis S; Priglinger SG
Biomedicines; 2022 Dec; 11(1):. PubMed ID: 36672611
[TBL] [Abstract][Full Text] [Related]
25. Current Management of Patients with RPE65 Mutation-Associated Inherited Retinal Degenerations in Europe: Results of a Multinational Survey by the European Vision Institute Clinical Research Network.
Lorenz B; Tavares J; van den Born LI; Marques JP; Scholl HPN;
Ophthalmic Res; 2021; 64(5):740-753. PubMed ID: 33684911
[TBL] [Abstract][Full Text] [Related]
26. Multi-luminance mobility testing after gene therapy in the context of retinal functional diagnostics.
Jung R; Kempf M; Holocher S; Kortüm FC; Stingl K; Stingl K
Graefes Arch Clin Exp Ophthalmol; 2024 Feb; 262(2):601-607. PubMed ID: 37768368
[TBL] [Abstract][Full Text] [Related]
27. Gene therapy for RPE65-related retinal disease.
Miraldi Utz V; Coussa RG; Antaki F; Traboulsi EI
Ophthalmic Genet; 2018 Dec; 39(6):671-677. PubMed ID: 30335549
[TBL] [Abstract][Full Text] [Related]
28. The Natural History of Inherited Retinal Dystrophy Due to Biallelic Mutations in the RPE65 Gene.
Chung DC; Bertelsen M; Lorenz B; Pennesi ME; Leroy BP; Hamel CP; Pierce E; Sallum J; Larsen M; Stieger K; Preising M; Weleber R; Yang P; Place E; Liu E; Schaefer G; DiStefano-Pappas J; Elci OU; McCague S; Wellman JA; High KA; Reape KZ
Am J Ophthalmol; 2019 Mar; 199():58-70. PubMed ID: 30268864
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.
Russell S; Bennett J; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; McCague S; Cross D; Marshall KA; Walshire J; Kehoe TL; Reichert H; Davis M; Raffini L; George LA; Hudson FP; Dingfield L; Zhu X; Haller JA; Sohn EH; Mahajan VB; Pfeifer W; Weckmann M; Johnson C; Gewaily D; Drack A; Stone E; Wachtel K; Simonelli F; Leroy BP; Wright JF; High KA; Maguire AM
Lancet; 2017 Aug; 390(10097):849-860. PubMed ID: 28712537
[TBL] [Abstract][Full Text] [Related]
30. A Cross-Sectional and Longitudinal Study of Retinal Sensitivity in RPE65-Associated Leber Congenital Amaurosis.
Kumaran N; Rubin GS; Kalitzeos A; Fujinami K; Bainbridge JWB; Weleber RG; Michaelides M
Invest Ophthalmol Vis Sci; 2018 Jul; 59(8):3330-3339. PubMed ID: 30025081
[TBL] [Abstract][Full Text] [Related]
31. Inflammation after Voretigene Neparvovec Administration in Patients with RPE65-Related Retinal Dystrophy.
Kessel L; Christensen UC; Klemp K
Ophthalmology; 2022 Nov; 129(11):1287-1293. PubMed ID: 35760216
[TBL] [Abstract][Full Text] [Related]
32. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement.
Cideciyan AV; Jacobson SG; Beltran WA; Sumaroka A; Swider M; Iwabe S; Roman AJ; Olivares MB; Schwartz SB; Komáromy AM; Hauswirth WW; Aguirre GD
Proc Natl Acad Sci U S A; 2013 Feb; 110(6):E517-25. PubMed ID: 23341635
[TBL] [Abstract][Full Text] [Related]
33. Gene Therapy in Hereditary Retinal Dystrophies: The Usefulness of Diagnostic Tools in Candidate Patient Selections.
Malvasi M; Casillo L; Avogaro F; Abbouda A; Vingolo EM
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762059
[TBL] [Abstract][Full Text] [Related]
34. The effect of human gene therapy for RPE65-associated Leber's congenital amaurosis on visual function: a systematic review and meta-analysis.
Wang X; Yu C; Tzekov RT; Zhu Y; Li W
Orphanet J Rare Dis; 2020 Feb; 15(1):49. PubMed ID: 32059734
[TBL] [Abstract][Full Text] [Related]
35. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial.
Hauswirth WW; Aleman TS; Kaushal S; Cideciyan AV; Schwartz SB; Wang L; Conlon TJ; Boye SL; Flotte TR; Byrne BJ; Jacobson SG
Hum Gene Ther; 2008 Oct; 19(10):979-90. PubMed ID: 18774912
[TBL] [Abstract][Full Text] [Related]
36. RPE65 Mutations in Two Japanese Families with Leber Congenital Amaurosis.
Katagiri S; Hayashi T; Kondo M; Tsukitome H; Yoshitake K; Akahori M; Ikeo K; Tsuneoka H; Iwata T
Ophthalmic Genet; 2016 Jun; 37(2):161-9. PubMed ID: 25495949
[TBL] [Abstract][Full Text] [Related]
37. Visual function and retinal changes after voretigene neparvovec treatment in children with biallelic RPE65-related inherited retinal dystrophy.
Testa F; Melillo P; Di Iorio V; Iovino C; Farinaro F; Karali M; Banfi S; Rossi S; Della Corte M; Simonelli F
Sci Rep; 2022 Oct; 12(1):17637. PubMed ID: 36271235
[TBL] [Abstract][Full Text] [Related]
38. Outcomes and Adverse Effects of Voretigene Neparvovec Treatment for Biallelic
Kiraly P; Cottriall CL; Taylor LJ; Jolly JK; Cehajic-Kapetanovic J; Yusuf IH; Martinez-Fernandez de la Camara C; Shanks M; Downes SM; MacLaren RE; Fischer MD
Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892166
[TBL] [Abstract][Full Text] [Related]
39. Subretinal deposits in young patients treated with voretigene neparvovec-rzyl for RPE65-mediated retinal dystrophy.
Lopez J; Borchert M; Lee TC; Nagiel A
Br J Ophthalmol; 2023 Mar; 107(3):299-301. PubMed ID: 35835501
[TBL] [Abstract][Full Text] [Related]
40. Differential macular morphology in patients with RPE65-, CEP290-, GUCY2D-, and AIPL1-related Leber congenital amaurosis.
Pasadhika S; Fishman GA; Stone EM; Lindeman M; Zelkha R; Lopez I; Koenekoop RK; Shahidi M
Invest Ophthalmol Vis Sci; 2010 May; 51(5):2608-14. PubMed ID: 19959640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
